Moderna climbs on full FDA nod for COVID shot in children aged six months or older

Shares of vaccine maker Moderna MRNA.O rise 3.3% to over three-months high of $33.87

MRNA says U.S. FDA approved its COVID-19 vaccine, Spikevax, in children aged six months through 11 years who are at an increased risk of the disease

Co expects the updated shot to be available for eligible populations in the U.S. for the 2025-26 respiratory virus season

*Piper Sandler analysts expect Moderna's COVID vaccine sales to "bottom" in 2025

Estimate new vaccine approvals to boost product sales to $3.1 billion in 2026 and $4.5 billion in 2027

Up to last close, stock down 21.1% YTD